Zymeworks signed a cope with Jazz Prescription drugs to develop and commercialize Zymeworks’ lead drug candidate, zanidatamab, which targets the most cancers marker HER2.
Zymeworks will obtain an upfront cost of $50 million and a second cost of $325 million, at Jazz’s possibility, following the discharge of topline knowledge from an ongoing scientific trial. That trial is testing the agent as a second-line therapy for HER2-positive biliary tract most cancers; zanidatamab can be being examined in opposition to different tumor sorts in separate research.
Zymeworks can also obtain additional funds on completion of future regulatory and business milestones, bringing the overall worth of the deal as much as $1.76 billion, plus royalties on gross sales. Vancouver, B.C.-based Zymeworks has 86 workers working in R&D in Seattle.
